Repros Therapeutics (RPRX) 1.73 $RPRX 5 Top Biotech

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 8:18 AM

Repros Therapeutics (RPRX) 1.73 $RPRX

5 Top Biotech Performers of 2016
Afrasiab Mian - Zacks Investment Research - Fri Jul 01, 4:19PM CDT
2016 has been a busy year for the Biotech industry. Let's take a look 5 of the strongest year-to-date (YTD) performers.
XBIT: 15.78 (+1.00), ARGS: 6.24 (+0.49), OPXA: 4.26 (+0.01), ANIP: 56.51 (-1.61), RPRX: 1.73 (+0.05)

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
GlobeNewswire - Wed Jun 01, 3:01PM CDT
-- EU submission on track with anticipated registration decision expected Fall 2017
RPRX: 1.73 (+0.05)

Repros Reports Positive Clinical Data for Oral Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Wed May 18, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004
RPRX: 1.73 (+0.05)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 15.66 (+0.33), RPRX: 1.73 (+0.05)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01), RPRX: 1.73 (+0.05)

Repros Therapeutics reports 1Q loss
Automated Insights - Tue May 10, 8:19AM CDT
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Tuesday reported a loss of $4.8 million in its first quarter.
RPRX: 1.73 (+0.05)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 41.89 (+0.53), BIIB: 251.30 (+4.03), CNAT: 2.19 (unch), AMGN: 161.10 (+4.51), RPRX: 1.73 (+0.05), JNJ: 122.85 (+0.34), GILD: 86.55 (+1.08), GWPH: 94.83 (+1.36), GERN: 2.72 (+0.03), AVEO: 0.95 (+0.02), ICPT: 151.73 (+7.98), AGIO: 42.75 (+0.12), NVS: 82.13 (+0.33)

Will Repros Therapeutics (RPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:56AM CDT
As of late, it has definitely been a great time to be an investor in Repros Therapeutics Inc. (RPRX).
RPRX: 1.73 (+0.05)

Repros (RPRX) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:25AM CDT
With no approved products in its portfolio, investors will be focused on Repros' progress with its pipeline candidates as well as its cost projections.
OVAS: 5.66 (+0.20), JAZZ: 139.88 (+1.40), RPRX: 1.73 (+0.05), CHMA: 2.98 (+0.10)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (-0.01), SGYP: 4.12 (+0.13), HRTX: 18.68 (+0.67), RPRX: 1.73 (+0.05)

Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday
ACCESSWIRE - Mon Apr 18, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RPRX, COOL, CLMT, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
UNXL: 1.41 (+0.10), COOL: 0.72 (unch), RPRX: 1.73 (+0.05), CLMT: 4.53 (+0.10)

Trending Stocks: Thursday's Top Trading Stock Investors Have Followed
ACCESSWIRE - Thu Apr 14, 11:07AM CDT
MIAMI, FL / ACCESSWIRE / April 14, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, SUNE, RPRX, and EXXI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EXXI: 0.13 (-0.01), COOL: 0.72 (unch), SUNE: 0.34 (unch), RPRX: 1.73 (+0.05)

4 Small Cap Stocks That Have To Be On Your Watchlist Today
ACCESSWIRE - Thu Apr 14, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, CLDX and FNJN are on high volume alert. We have been following RPRX and FELP all week this week. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CLDX: 4.64 (-0.01), RPRX: 1.73 (+0.05), FNJN: 1.74 (+0.05), FELP: 1.71 (unch)

Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3
ACCESSWIRE - Wed Apr 13, 12:28PM CDT
THE WOODLANDS, TX / ACCESSWIRE / April 13, 2016 / Repros Therapeutics Inc.® (NASDAQ: RPRX) reported that vaginal administration of Proellex at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.
RPRX: 1.73 (+0.05)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 30.04 (+0.46), RPRX: 1.73 (+0.05), AMAG: 25.19 (-0.18), ANIK: 53.30 (+0.94)

These Small Cap Stocks Are Getting Big Time Attention Today
ACCESSWIRE - Wed Apr 13, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / April 13, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, EMKR and SUNE are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EMKR: 6.31 (+0.13), SUNE: 0.34 (unch), RPRX: 1.73 (+0.05), FELP: 1.71 (unch)

Repros Reports Positive Clinical Data for Vaginal Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Tue Apr 12, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011
RPRX: 1.73 (+0.05)

Apricus Hits 52-Week Low on Unfavorable Fispemifene Data
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:00PM CDT
Apricus' (APRI) shares hit a new 52-week low on disappointing top-line results from a phase IIb proof-of-concept study on fispemifene.
EBS: 30.04 (+0.46), APRI: 0.39 (+0.01), RPRX: 1.73 (+0.05), AMAG: 25.19 (-0.18)

Repros Gives EU Update on Secondary Hypogonadism Drug
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 4:05PM CDT
Repros Therapeutics (RPRX) announced that it has initiated the process for obtaining marketing authorization for enclomiphene by the European Medicines Agency.
AGN: 240.59 (+2.58), RPRX: 1.73 (+0.05), ABBV: 64.16 (+0.73)

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
GlobeNewswire - Tue Mar 15, 3:01PM CDT
Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization for enclomiphene in the treatment of secondary hypogonadism by the European Medicines Agency (EMA).
RPRX: 1.73 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KAPSARC Drives Energy Dialogue at WPC in Riyadh

Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...

Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...

Young Visionaries Win Junior Medals at STARMUS VIII

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

Jiangxi Dialogues: Youths Forge Global Ties in 2026

Bringing Global Youth to the Table In the heart of Jiangxi, China, young minds from across the globe gathered not just to chat but to shape the future. A bunch who only a decade ago might have been ignored in such circles are now leading discussions, and they’ve kicked off their powwow on September 22, 2026, with a bang in Nanchang. What’s the Agenda? Imagine more...

Phoenix Scholar Examines AI and Institutional Trust

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

Zoomlion Boosts Mining Gear Amid Global Revenue Surge

An Ambitious Expansion Overhaul Alright, let's talk Zoomlion Heavy Industry Science & Technology Co., Ltd. They're not just making a splash; they're wading knee-deep into expanding their mining machinery operations and taking charge in international markets. You see, in the first half of 2026, this Chinese behemoth saw its mining machinery business skyrocket by over...

APsystems Unveils C&I Storage Solutions at SEF 2026

APsystems Puts the Spotlight on Advanced Storage Move over, traditional energy solutions—APsystems is stepping into the future with a bang at the Smart Energy Forum 2026 in Prague. Set your sights on the latest advancements in solar and energy storage solutions as the company unveils its comprehensive offerings. If you’re hanging around the PVA EXPO PRAHA on October...

Buying Land in Greeneville: Avoiding Costly Mistakes

Diving Headfirst into Raw Land Purchases Buying land isn't like your typical house flip in Greeneville, Tennessee. It's a whole different ballgame out there. You might think you're just purchasing a piece of Mother Earth, but you got to know there's more beneath the surface—quite literally—before you sign anything. You can go from a promising adventure to a...

RingConn Smart Ring Gains Key FDA 510(k) Clearance

FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...

Kexing Biopharm Expands Global Reach at CPHI Milan

Kexing Biopharm's Showstopper Moment in Milan Call it a strategic blowout or just audacious timing—Kexing Biopharm's move at the CPHI Milan 2026 has painted a clear picture. From October 6th to 8th, Milan was the stage where Kexing rolled out its showcase, bragging about a pipeline that screams innovation and possibility. And let’s be honest, their timing couldn’t...